Monopar Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Monopar Therapeutics Inc (MNPR)

Q3 202624 Jun – 12 Aug 2026

▲3

Monopar Advances ALXN1840 Toward FDA Filing, Cash Secured

New Phase 3 data show ALXN1840 beats standard of care Monopar reported new Phase 3 analyses showing its Wilson disease drug ALXN1840 gave better neurologic and overall clinical improvement than standard treatment. This strengthens the case for FDA approval, making the company's future revenue look more likely and supporting a higher stock price.
This is the core clinical evidence that de-risks the lead drug and drives the investment case.
FDA grants Rare Pediatric Disease designation The FDA gave ALXN1840 a Rare Pediatric Disease designation. If approved, Monopar could receive a priority review voucher worth millions, which can be sold or used to speed up another drug review. This adds potential cash and shortens timelines, boosting the stock.
This new regulatory win adds a valuable asset and speeds up potential approval.
Rolling NDA submission underway for ALXN1840 Monopar has started submitting its application to the FDA for ALXN1840 in pieces, with completion expected in a few months. This moves the drug closer to approval and potential sales, a key milestone that investors watch closely.
The start of the NDA submission is a concrete step toward commercialization, directly affecting future revenue prospects.
Q2 loss widens but cash runway through 2027 Monopar's quarterly loss grew to $5.3 million from $2.5 million a year ago, mainly due to higher spending on drug development. However, it has $134.3 million in cash, enough to fund operations through at least end of 2027. The loss is a concern, but the strong cash position reduces near-term financing risk.
This shows the financial trade-off: higher spending now but enough cash to reach key milestones without immediate dilution.

July 202624 Jun – 12 Aug 2026

▲3

Monopar Advances ALXN1840 Toward FDA Filing, Cash Secured

New Phase 3 data show ALXN1840 beats standard of care Monopar reported new Phase 3 analyses showing its Wilson disease drug ALXN1840 gave better neurologic and overall clinical improvement than standard treatment. This strengthens the case for FDA approval, making the company's future revenue look more likely and supporting a higher stock price.
This is the core clinical evidence that de-risks the lead drug and drives the investment case.
FDA grants Rare Pediatric Disease designation The FDA gave ALXN1840 a Rare Pediatric Disease designation. If approved, Monopar could receive a priority review voucher worth millions, which can be sold or used to speed up another drug review. This adds potential cash and shortens timelines, boosting the stock.
This new regulatory win adds a valuable asset and speeds up potential approval.
Rolling NDA submission underway for ALXN1840 Monopar has started submitting its application to the FDA for ALXN1840 in pieces, with completion expected in a few months. This moves the drug closer to approval and potential sales, a key milestone that investors watch closely.
The start of the NDA submission is a concrete step toward commercialization, directly affecting future revenue prospects.
Q2 loss widens but cash runway through 2027 Monopar's quarterly loss grew to $5.3 million from $2.5 million a year ago, mainly due to higher spending on drug development. However, it has $134.3 million in cash, enough to fund operations through at least end of 2027. The loss is a concern, but the strong cash position reduces near-term financing risk.
This shows the financial trade-off: higher spending now but enough cash to reach key milestones without immediate dilution.

Latest24 Jun – 12 Aug 2026

▲3

Monopar Advances ALXN1840 Toward FDA Filing, Cash Secured

New Phase 3 data show ALXN1840 beats standard of care Monopar reported new Phase 3 analyses showing its Wilson disease drug ALXN1840 gave better neurologic and overall clinical improvement than standard treatment. This strengthens the case for FDA approval, making the company's future revenue look more likely and supporting a higher stock price.
This is the core clinical evidence that de-risks the lead drug and drives the investment case.
FDA grants Rare Pediatric Disease designation The FDA gave ALXN1840 a Rare Pediatric Disease designation. If approved, Monopar could receive a priority review voucher worth millions, which can be sold or used to speed up another drug review. This adds potential cash and shortens timelines, boosting the stock.
This new regulatory win adds a valuable asset and speeds up potential approval.
Rolling NDA submission underway for ALXN1840 Monopar has started submitting its application to the FDA for ALXN1840 in pieces, with completion expected in a few months. This moves the drug closer to approval and potential sales, a key milestone that investors watch closely.
The start of the NDA submission is a concrete step toward commercialization, directly affecting future revenue prospects.
Q2 loss widens but cash runway through 2027 Monopar's quarterly loss grew to $5.3 million from $2.5 million a year ago, mainly due to higher spending on drug development. However, it has $134.3 million in cash, enough to fund operations through at least end of 2027. The loss is a concern, but the strong cash position reduces near-term financing risk.
This shows the financial trade-off: higher spending now but enough cash to reach key milestones without immediate dilution.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.